BIO-TECHNE CORP shareholders Q2 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Swiss National Bank 170,200$58,998,0000.04%
Gulf International Bank (UK) Ltd 6,543$2,280,0000.04%
Petrus Trust Company, LTA 808$280,0000.04%
HARTFORD INVESTMENT MANAGEMENT CO 3,773$1,308,0000.04%
TRAN CAPITAL MANAGEMENT, L.P. 1,000$347,0000.04%
Redpoint Investment Management Pty Ltd 950$329,0000.04%
Utah Retirement Systems 6,964$2,414,0000.04%
BRADLEY FOSTER & SARGENT INC/CT 4,237$1,469,0000.04%
FORSTA AP-FONDEN 8,500$2,946,0000.04%
IFM Investors Pty Ltd 6,180$2,142,0000.04%
State of Alaska, Department of Revenue 9,042$3,133,0000.04%
RHUMBLINE ADVISERS 75,784$26,270,0000.04%
NEW MEXICO EDUCATIONAL RETIREMENT BOARD 2,200$763,0000.04%
Treasurer of the State of North Carolina 16,999$5,893,0000.04%
Arizona State Retirement System 10,965$3,801,0000.04%
PEREGRINE CAPITAL MANAGEMENT LLC 3,519$1,220,0000.04%
SOA Wealth Advisors, LLC. 367$127,0000.04%
STATE OF WISCONSIN INVESTMENT BOARD 39,375$13,649,0000.04%
Covestor Ltd 133$46,0000.04%
Cerity Partners LLC 9,427$3,268,0000.04%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2022. To view BIO-TECHNE CORP's shareholder history, click here.